The clinical outcomes revealed that MAGE‐A3+AS15 vaccine alone did not show therapeutic efficacy in these cancer patients and the development of the therapeutic vaccine for use in these malignancies has been stopped.[139, 140] A phase 2 study of MAGE‐A3+AS15 vaccine in patients who experienced surgical removal of bladder cancer was also terminated (NCT01435356). This evidence concerns the gene MAGEA3 and urinary bladder carcinoma.